soluble interleukin-6 receptor

Soluble interleukin-6 receptor (sIL-6R) refers to the non-membrane-bound form of the IL-6 receptor alpha subunit, which is being investigated in its recombinant or engineered forms as a therapeutic agent. Naturally, endogenous sIL-6R mediates IL-6 trans-signaling by binding to IL-6 and subsequently interacting with the ubiquitously expressed gp130 protein on cell surfaces, a process often associated with pro-inflammatory activities. Therapeutic candidates like engineered selected-sequence sIL-6R (seIL-6R) or mutant sIL-6R (mIL-6R) are designed to act as decoy receptors or competitive inhibitors. These variants bind to circulating IL-6 but are modified to prevent the activation of the gp130 signaling complex, thereby neutralizing IL-6-mediated inflammation and potentially inhibiting tumor cell migration and survival. Development is currently in the preclinical stage for indications including breast cancer, pancreatic cancer, and various chronic inflammatory conditions.

Other names

sIL-6RsIL6RsIL 6Rsoluble IL-6 receptorrecombinant soluble interleukin-6 receptorsoluble interleukin-6 receptor alpha